Back to EveryPatent.com
United States Patent |
5,262,427
|
Nielson
,   et al.
|
November 16, 1993
|
3-substituted and optionally 1-substituted azacyclic or azabicyclic
compounds, pharmaceutical compositions, thereof and their use as
stimulants of cognitive functions
Abstract
Azacyclic compounds selected from the group consisting of
##STR1##
wherein R.sup.1 is H or C.sub.1-6 -alkyl
R.sup.3 is
##STR2##
wherein R' is C.sub.3-8 -alkyl, cyclopropyl, C.sub.4-8 -cycloalkyl, benzyl
which may be substituted, or C.sub.1-4 -alkoxy-C.sub.1-4 -alkyl, and
R" is H or C.sub.1-8 -alkyl or C.sub.1-6 -alkoxy or C.sub.1-4
-alkoxy-C.sub.1-4 -alkyl or aryl, and
R'" is H or C.sub.1-6 -alkyl or C.sub.4-8 -cycloalkyl; and
R.sup.4 is H, C.sub.1-8 -alkyl or Cl; and
##STR3##
provided that R.sup.3 is not
##STR4##
wherein R' is C.sub.3-8 -alkyl, cyclopropyl or C.sub.1-3 -alkoxymethyl,
and provided that R.sup.3 is not --CH.dbd.N--OR'", wherein R'" is H or
C.sub.1-6 -alkyl, when the compounds of formula I is
##STR5##
and a salt thereof with a pharmaceutically-acceptable acid. The new
compounds are useful in improving the cognitive functions of the forebrain
and hippocampus of mammals, and are useful in the treatment of Alzheimer's
disease.
Inventors:
|
Nielson; Lone (Kobenhavn, DK);
Watjen; Frank (Vaerlose, DK);
Kindtler; Jens W. (Kokkedal, DK);
Olesen; Preben H. (Kobenhavn, DK);
Sauerberg; Per (Valby, DK)
|
Assignee:
|
Novo Nordisk A/S (Bagsvaerd, DK)
|
Appl. No.:
|
268940 |
Filed:
|
November 8, 1988 |
Foreign Application Priority Data
| Nov 13, 1987[DK] | 5952/87 |
| Dec 28, 1987[DK] | 6870/87 |
| Mar 02, 1988[DK] | 1102/88 |
Current U.S. Class: |
514/304; 514/305; 514/315; 514/326; 514/340; 546/124; 546/125; 546/133; 546/209; 546/246; 546/269.4; 546/271.4; 546/272.1; 546/334 |
Intern'l Class: |
C07D 413/04; A61K 031/41 |
Field of Search: |
514/304,305,315,326,340
546/124,125,133,209,246,275,277,334
|
References Cited
U.S. Patent Documents
3265692 | Aug., 1966 | Harsanyi et al. | 546/209.
|
4144343 | Mar., 1979 | Baldwin et al. | 546/277.
|
4518601 | May., 1985 | Kristiansen et al. | 546/277.
|
4710508 | Dec., 1987 | Bergmeier et al. | 546/334.
|
4786648 | Nov., 1988 | Bergmeier et al. | 546/334.
|
4837241 | Jun., 1989 | Jensen et al. | 514/326.
|
4866077 | Sep., 1989 | Bogeso et al. | 514/326.
|
4925858 | May., 1990 | Bogeso et al. | 546/209.
|
4927837 | May., 1990 | Galliani et al. | 546/246.
|
4933353 | Jun., 1990 | Jensen et al. | 546/277.
|
4937239 | Jun., 1990 | Lauffer et al. | 546/133.
|
4968691 | Nov., 1990 | Orlek et al. | 546/133.
|
Foreign Patent Documents |
0239309 | Sep., 1987 | EP.
| |
0307141 | Sep., 1988 | EP.
| |
296721 | Dec., 1988 | EP | 546/277.
|
323864 | Jul., 1989 | EP | 546/133.
|
2213152 | Aug., 1989 | GB | 546/246.
|
Other References
Tamura et al., Chemical Abstracts, vol. 84, No. 175159v (1976).
Wells et al., Chemical Abstracts, vol. 67, No. 99958m (1967).
Baker et al., Chemical Abstracts, vol. 109, No. 54780s (1988).
Beecham Group PLC, Chemical Abstracts, vol. 110, No. 115165q (1989).
Bergmeier et al., Chemical Abstracts, vol. 110, No. 57518u (1989).
Bogeso et al., Chemical Abstracts, vol. 110, No. 192831f (1989).
Galliani et al., Chemical Abstracts, vol. 108, No. 204502y (1988).
Mastafanova et al., Chemical Abstracts, vol. 64, No. 12642f (1966).
Saunders et al., Chemical Abstracts, vol. 111, No. 39157s (1989).
|
Primary Examiner: Lee; Mary C.
Assistant Examiner: Powers; Fiona T.
Attorney, Agent or Firm: Zelson; Steve T., Lambiris; Elias J.
Claims
We claim:
1. A compound of formula I
##STR31##
wherein p1 R.sup.1 is H or C.sub.1-6 -alkyl; R.sup.3 is
##STR32##
wherein R' is benzyl or methoxybenzyl;
R.sup.4 is H, C.sub.1-8 -alkyl or Cl; and
##STR33##
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, wherein R.sup.1 is H or methyl and
R.sup.4 is H or methyl.
3. The compound according to claim 2 which is
3-(3-(2-methoxybenzyl)-1,2,4-oxadiazol-5-yl)-1-methyl-1,2,5,6-tetrahydropy
ridine or a pharmaceutically acceptable salt thereof.
4. A compound of formula II
##STR34##
wherein R.sup.1 is H or C.sub.1-6 -alkyl;
R.sup.3 is
##STR35##
wherein R' is C.sub.3-8 -cycloalkyl, benzyl or methoxybenzyl and R" is H,
C.sub.1-8 -alkyl, C.sub.1-6 -alkoxy, C.sub.1-4 -alkoxy-C.sub.1-4 -alkyl or
phenyl;
R.sup.4 is H, C.sub.1-8 -alkyl or Cl; and
##STR36##
or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 4, wherein R.sup.1 is H or methyl and
R.sup.4 is H or methyl.
6. The compound according to claim 5 which is
2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-8-methyl-8-azabicyclo[3.2.1]oct-2-e
ne or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 5 which is
3-chloro-2-(5-butyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene or a
pharmaceutically acceptable salt thereof.
8. The compound according to claim 5 which is
3-chloro-2-(5-methoxymethyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene or
a pharmaceutically acceptable salt thereof.
9. The compound according to claim 5 which is
3-chloro-2-(5-methyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene or a
pharmaceutically acceptable salt thereof.
10. The compound according to claim 5 which is
3-chloro-8-methyl-2-(5-methyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene
or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 5 which is
2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1oct-2-ene or a
pharmaceutically acceptable salt thereof.
12. The compound according to claim 5 which is
3-chloro-2-(5-phenyl-3-isoxazolyl)-8-azabicyclo[3.2.1oct-2-ene or a
pharmaceutically acceptable salt thereof.
13. The compound according to claim 5 which is
2-(5-phenyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene or a
pharmaceutically acceptable salt thereof.
14. The compound according to claim 5 which is
3-chloro-8-methyl-2-(5-phenyl-3-isoxazolyl)-8-azabicyclo[3.2.1oct-2-ene or
a pharmaceutically acceptable salt thereof.
15. A compound of formula III
##STR37##
wherein R.sup.3 is
##STR38##
wherein R' is C.sub.3-8 -cycloalkyl, benzyl or methoxybenzyl; and
##STR39##
or a pharmaceutically acceptable salt thereof.
16. The compound according to claim 15 which is
3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-2,3-didehydroquinuclidine or a
pharmaceutically acceptable salt thereof.
17. The compound according to claim 15 which is
3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-quinuclidine or a pharmaceutically
acceptable salt thereof.
18. The compound according to claim 15 which is
3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-2,3-didehydroquinuclidine or a
pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition suitable for use in treating Alzheimer's
disease, comprising an effective amount of a compound according to claim
1, 4 or 15 together with a pharmaceutically acceptable carrier or diluent.
20. The pharmaceutical composition according to claim 19 in the form of an
oral dosage unit containing 1-100 mg of the active compound.
21. A method for treating Alzheimer's disease comprising administering to a
subject in need thereof an effective amount of a compound according to
claim 1, 4 or 15.
22. A method for treating Alzheimer's disease, comprising administering to
a subject in need thereof a pharmaceutical composition according to claim
19.
Description
The present invention relates to therapeutically active azacyclic
compounds, a method of preparing the same and to pharmaceutical
compositions comprising the compounds. The novel compounds are useful as
stimulants of the cognitive function of the forebrain and hippocampus of
mammals and especially in the treatment of Alzheimer's disease.
Due to the in general improved health situation in the western world,
elderly-related diseases are much more common now than in the past and are
likely to be even more common in the future.
One of the elderly-related symptoms is a reduction of the cognitive
functions. This symptom is especially pronounced in the patophysiological
disease known as Alzheimer's disease. This disease is combined with, and
also most likely caused by, a up to 90% degeneration of the muscarinic
cholinergic neurons in nucleus basalis, which is part of substantia
innominata. These neurons project to the prefrontal cortex and hippocampus
and have a general stimulatory effect on the cognitive functions of the
forebrain as well as of hippocampus , namely learning, association,
consolidation, and recognition.
It is a characteristic of Alzheimer's disease that although the cholinergic
neurons degenerate, then the postsynaptic muscarinic receptors in the
forebrain and hippocampus still exist. Therefore muscarinic cholinergic
agonists are useful in the treatment of Alzheimer's disease and in
improving the cognitive functions of elderly people.
It is well known that arecoline (methyl
1-methyl-1,2,5,6-tetrahydropyridine-3-carboxylate) is such a cholinergic
agonist.
Arecoline however has a very short biological half life and a small
separation between central and peripheral muscarinic effects. Furthermore
arecoline is a rather toxic compound.
Accordingly it is an object of the invention to provide new muscarinic
cholinergic compounds.
The novel compounds of the invention of formula I are heterocyclic
compounds selected from the group consisting of:
##STR6##
wherein
R.sup.1 is H or C.sub.1-6 -alkyl
R.sup.3 is
##STR7##
R.sup.3 is C.sub.3-8 -alkyl, cyclopropyl, C.sub.4-8 -cycloalkyl, benzyl
which may be substituted or C.sub.1-4 -alkoxy-C.sub.1-4 -alkyl, and
R" is H or C.sub.1-8 -alkyl or C.sub.1-6 -alkoxy or C.sub.1-4
-alkoxy-C.sub.1-4 -alkyl or aryl, and
R'" is H or C.sub.1-6 -alkyl or C.sub.4-8 -cycloalkyl; and
R.sup.4 is H, C.sub.1-8 -alkyl or Cl;
##STR8##
provided that R.sup.3 is not
##STR9##
wherein R' is C.sub.3-8 -alkyl, cyclopropyl or C.sub.1-3 -alkoxymethyl,
and provided that R.sup.3 is not --CH.dbd.N--OR'", wherein R'" is H or
C.sub.1-6 -alkyl, when the compounds of formula I is
##STR10##
and a salt thereof with a pharmaceutically-acceptable acid.
Examples of such salts include inorganic and organic acid addition salts
such as hydrochloride, hydrobromide, sulphate, phosphate, acetate,
fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar
pharmaceutically-acceptable inorganic or organic acid addition salt.
The invention also relates to a method of preparing the above mentioned
compounds. This method comprises
a) reacting a reactive derivative of a compound selected from the group
consisting of
##STR11##
wherein R.sup.1, R.sup.4 and
##STR12##
have the meanings defined above, with a compound having the formula III
R'--C(.dbd.NOH)NH.sub.2 (III)
wherein R' has the meaning defined above to form a compound of the general
formula I, wherein R.sup.3 is
##STR13##
wherein R' has the meaning defined above, or
b) reacting a compound selected from the group consisting of
##STR14##
wherein R.sup.1, R.sup.4 and
##STR15##
have the meanings defined above, with NH.sub.2 OH, and reacting the
compound thus formed with R'--COCl or (R'CO).sub.2 O, wherein R' has the
meaning set forth above, to form a compound of formula I, wherein R.sup.3
is
##STR16##
wherein R' has the meaning defined above, or
c) reacting a compound selected from the group consisting of
##STR17##
wherein R.sup.1, R.sup.4 and
##STR18##
have the meanings defined above, with an alkene, alkyne or a equivalent
thereof, to form a compound of the general formula I, wherein R.sup.3 is
##STR19##
wherein R" has the meaning defined above, or
d) reacting a compound selected from the group consisting of
##STR20##
wherein R.sup.1, R.sup.4 and
##STR21##
have the meanings defined above, with a compound having the formula VII
NH.sub.2 --O--R'" (VII)
wherein R'" has the meaning set forth above, to form a compound of the
general formula I, wherein R.sup.3 is
--CH.dbd.N--O--R'"
wherein R'" as the meaning defined above.
e) reacting a compound selected from the group consisting of
##STR22##
wherein R.sup.1, R.sup.4 and
##STR23##
have the meanings defined above, with a compound having the formula
##STR24##
wherein R'" has the meaning set forth above to form a compound of the
general formula I wherein R.sup.3 is
##STR25##
wherein R'" has the meaning defined above.
f) reacting pyridine-3-carbaldehyde with a compound having the formula
##STR26##
wherein R'" has the meaning set forth above, followed by reaction with
R.sup.1 -hal wherein R.sup.1 has the meaning defined above, and reacting
the compound thus formed with NaBH.sub.4 to form a compound of the general
formula
##STR27##
g) reacting 3-acetylpyridine with a compound having the formula
##STR28##
wherein R" has the meaning set forth above followed by reaction with
NH.sub.2 --OSO.sub.3 H and R.sup.1 -hal wherein R.sup.1 has the meaning
defined above, and reacting the compound thus formed with NaBH.sub.4 to
form a compound of the general formula
##STR29##
h) reacting 3-ethynylpyridine with a compound having the formula
R"CN.sup.+ O.sup.-
wherein R" has the meaning set forth above followed by reaction with
R.sup.1 -hal wherein R.sup.1 has the meaning defined above, and reacting
the compound thus formed with NaBH.sub.4 to form a compound of the general
formula
##STR30##
*****
The pharmacological properties of the compounds of the invention can be
illustrated by determining their capability to inhibit the specific
binding of .sup.3 H-QNB (.sup.3 H-quinuclidinyl benzilate) by 50%. The
inhibitory effect of a substance on .sup.3 H-QNB binding to brain
membranes reflects the affinity of the substance for muscarinic
acetylcholine receptors. (Yamamura, H. I. and Snyder, S. H., Proc. Natl.
Acad. Sci. 71, 1725-29(1979). The test is carryed out as follows:
Fresh whole forebrain from male Wistar rats (200-250 g) is homogenized by
an Ultra-Turrax homogenizer (5-10 s) in volumes of 0.32M sucrose. The
homogenate is centrifuged at 4,300.times.g for 5 min. The pellet is
discarded and the supernatant centrifuged at 40,000.times.g for 15 min.
The final pellet is rehomogenized in 50 mM KH.sub.2 PO.sub.4, pH 7.1 (1000
ml per g of original tissue) and this crude membrane preparation is used
for binding assays. To 2.5 ml of tissue suspension is added 25 .mu.l of
test solution* and 25 .mu.l .sup.3 H-QNB (1 nM final concentration).
Samples are thoroughly mixed and incubated at 37.degree. C. for 20 min.
after incubation, samples are poured directly onto GF/C glass fiber
filters under suction and immediately washed 2 times with 10 ml of buffer
at 0.degree. C. Non-specific binding is determined in dublicate using
atropin (1 .mu.g/ml, final concentration) as the test substance. The
amounts of radioactivity on the filters are determined by conventional
liquid scintilation counting. Specific binding is total binding minus
non-specific binding.
* Test compound is dissolved in 10 ml 96% ethanol (if necessary, acidified
by 25 .mu.l 1N HCl and heated on a steambath for less than 5 minutes) at a
concentration of 0.22 mg/ml. Three dilutions are made in 48% ethanol (1.1
.mu.g/ml, 11 .mu.g/ml and 110 .mu.g/ml). Concentrations of 10, 100 and
1000 ng/ml (final concentration) are added to duplicate assays. 25-75%
inhibition of specific binding must be obtained, before calculation of
IC.sub.50.
The test value will be given as IC.sub.50 (the concentration/.mu.g/ml) of
the test substance which inhibits the specific binding of .sup.3 H-QNB by
50%).
##EQU1##
where C.sub.o is specific binding in control assays and C.sub.x is the
specific binding in the test assay (the calculation assumes normal
mass-action interaction).
The compound of the invention, together with a conventional adjuvant,
carrier, or diluent, and if desired in the form of a
pharmaceutically-acceptable acid addition salt thereof, may be placed into
the form of pharmaceutical compositions and unit dosages thereof, and in
such form may be employed as solids, such as tablets or filled capsules,
or liquids, such as solutions, suspensions, emulsions, elixirs, or
capsules filled with the same, all for oral use, in the form of
suppositories for rectal administration; or in the form of sterile
injectable solutions for parenteral (including subcutaneous) use. Such
pharmaceutical compositions and unit dosage forms thereof may comprise
conventional ingredients in conventional proportions, with or without
additional active compounds or principles, and such unit dosage forms may
contain any suitable effective muscarinic cholinergic agonistic amount of
the active ingredient commensurate with the intended daily dosage range to
be employed. Tablets containing ten (10) milligrams of the active
ingredient or, more broadly, one (1) to hundred (100) milligrams, per
tablet, are accordingly suitable representative unit dosage forms.
The compounds of this invention can thus be used for the formulation of
pharmaceutical preparations, e.g. for oral and parenteral administration
to mammals including humans, in accordance with conventional methods of
galenic pharmacy.
Conventional excipients are such pharmaceutically acceptable organic or
inorganic carrier substances suitable for parenteral or enteral
application which do not deleteriously react with the active compounds.
Examples of such carriers are water, salt solutions, alcohols, polyethylene
glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose,
magnesium stearate, talc, silicic acid, fatty acid monoglycerides and
diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose
and polyvinylpyrrolidone.
The pharmaceutical preparations can be sterilized and mixed, if desired,
with auxiliary agents, emulsifiers, salt for influencing osmotic pressure,
buffers and/or coloring substances and the like, which do not
deleteriously react with the active compounds.
For parenteral application, particularly suitable are injectable solutions
or suspensions, preferably aqueous solutions with the active compound
dissolved in polyhydroxylated castor oil.
Ampoules are convenient unit dosage forms.
Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or
binder or the like, the carrier preferably being lactose and/or corn
starch and/or potato starch, are particularly suitable for oral
application. A syrup, elixir of the like can be used in cases where a
sweetened vehicle can be employed.
Generally, the compounds of this invention are dispensed in unit form
comprising 1-100 mg in a pharmaceutically acceptable carrier per unit
dosage.
The dosage of the compounds according to this invention is 1-100 mg/day
preferably 10-70 mg/day when administered to patients, e.g. humans, as a
drug.
A typical tablet which may be prepared by conventional tabletting
techniques contains:
______________________________________
Active compound 5.0 mg
Lactosum 67.8 mg Ph.Eur.
Avicel .RTM. 31.4 mg
Amberlite .RTM. IRP 88
1.0 mg
Magnesii stearas 0.25 mg Ph.Eur.
______________________________________
Due to the high muscarinic cholinergic receptor agonistic activity, the
compounds of the invention are extremely useful in the treatment symptoms
related to a reduction of the cognitive functions of the brain of mammals
, when administered in an amount effective for stimulating the cognitive
functions of the forebrain and hippocampus. The important stimulating
activity of the compounds of the invention includes both activity against
the pathophysiological disease, Alzheimer's disease as well as against
normal degeneration of brain function. The compounds of the invention may
accordingly be administered to a subject, e.g., a living animal body,
including a human, in need of stimulation of the cognitive functions of
the forebrain and hippocampus, and if desired in the form of a
pharmaceutically-acceptable acid addition salt thereof (such as the
hydrobromide, hydrochloride, or sulfate, in any event prepared in the
usual or conventional manner, e.g., evaporation to dryness of the free
base in solution together with the acid), ordinarily concurrently,
simultaneously, or together with a pharmaceutically-acceptable carrier or
diluent, especially and preferably in the form of a pharmaceutical
composition thereof, whether by oral, rectal, or parenteral (including
subcutaneous) route, in an effective forebrain and hippocampus stimulating
amount, and in any event an amount which is effective for improving the
cognitive function of mammals due to their muscarinic cholinergic receptor
agonistic activity. Suitable dosage ranges are 1-100 milligrams daily,
10-100 milligrams daily, and especially 30-70 milligrams daily, depending
as usual upon the exact mode of administration, form in which
administered, the indication toward which the administration is directed,
the subject involved and the body weight of the subject involved, and the
preference and experience of the physician or veterinarian in charge.
The invention will now be described in further detail with reference to the
following examples:
EXAMPLE 1
2-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)-8-methyl-8-azabicyclo[3.2.1]oct-2-en
e oxalate
Sodium (56.6 mg, 2.46 mmol) was dissolved in absolute ethanol (12 ml).
Molecular sieves (Type 4A, 1.3 g) and cyclopropancarboxamide oxime (330
mg, 3.30 mmol) were added and the resulting mixture vigorously stirred for
15 min. before addition of cocaine hydrochloride (280 mg, 0.82 mmol). The
reaction mixture was heated at 80.degree. for 20 hours. The solution was
then filtered from the molecular sieves and the solvent was removed in
vacuo. Ether (75 ml) was added to the residue followed by water (20 ml)
and the organic phase was separated. The aqueous phase was extracted with
ether (2-75 ml), and the combined ether phases were dried (MgSO.sub.4,
filtered and evaporated.
The title compound was isolated as the oxalate, which was recrystallized
from absolute ethanol/ether. M.p. 117.degree. C.
In exactly the same manner the following compound was made:
2-(3-n-butyl-1,2,4-oxadiazol-5-yl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene
oxalate. M.p. 174.degree. C.
EXAMPLE 2
2-(3-Isopropyl-1,2,4-oxadiazol-5-yl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene
oxalate
Sodium (303 mg, 13.2 mmol) was dissolved in absolute ethanol (60 ml).
Molecular sieves (Type 4A, 7 g) and isopropancarboxamide oxime (2.64 g,
26.4 mmol) were added and the resulting mixture vigorously stirred for 15
min. before addition of cocaine (2.0 g, 6.6 mmol). The reaction mixture
was heated at 80.degree. for 24 h and at room temperature for 24 h. The
solution was then filtered from the molecular sieves and the solvent was
removed in vacuo. Ether (250 ml) was added to the residue followed by
water (100 ml) and the organic phase was separated. The aqueous phase was
extracted with ether (2.times.250 ml), and the combined ether phases were
dried (MgSO.sub.4), filtered and evaporated to give an oil, which was
chromatographed on silica gel eluting with ethylacetate and ethanol. The
title compound was isolated as the oxalate, which was recrystallized from
absolute ethanol/ether. M.p. 162.degree. C.
In exactly the same manner the following compounds were made:
2-(3-Methoxymethyl-1,2,4-oxadiazol-5-yl)-8-methyl-8-azabicyclo[3.2.1]oct-2-
ene oxalate M.p. 139.degree. C.
2-(3-(2-Methoxyethyl)-1,2,4-oxadiazol-5-yl)-8-methyl-8-azabicyclo[3.2.1]oct
-2-ene oxalate M.p. 165.degree. C.
EXAMPLE 3
2-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]oct-2-ene
hydrochloride
2-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)-methyl-8-azabicyclo[3.2.1]oct-2-ene
(525 mg, 2.3 mmol) was dissolved in dry dichlorethane (10 ml). The
solution was cooled on ice and 1-chloroethyl chloroformate (370 .mu.l, 3.4
mmol was added). The reaction mixture was heated under reflux for 1.5 h
and the solvent evaporated. Methanol (20 ml) was added and the mixture
heated under reflux for further 1.5 h. The mixture was treated with
charcoal, filtered and concentrated in vacuo.
The product was recrystallized from absolute ethanol/ether. M.p. 86.degree.
C.
In exactly the same manner the following compounds were made:
2-(3-(2-Methoxyethyl)-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]oct-2-ene
hydrochloride, M.p. 62 .degree. C.
2-(3-Isopropyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]oct-2-ene oxalate,
M.p. 168.degree. C.
EXAMPLE 4
3-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)-2,3-didehydroquinuclidine oxalate
Sodium (181 mg, 7.86 mmol) was dissolved in absolute ethanol (45 ml).
Molecular sieves (Type 4A, 5 g) and cyclopropancarboxamide oxime (786 mg,
7.86 mmol) were added and the resulting mixture vigorously stirred for 15
min. before addition of 3-methoxycarbonyl-2,3-didehydroquinuclidine, HCl;
prepared as described by Grob et al. in Helv. Chim. Acta. (1954), 37,
1689. The reaction mixture was heated at 80.degree. C. for 18 h. The
solution was then filtered from the molecular sieves and the solvent was
removed in vacuo. Ether (50 ml) was added to the residue followed by water
(25 ml) and the organic phase was separated. The aqueous phase was
extracted with ether (3.times.50 ml), and the combined ether phases were
dried (Na.sub.2 SO.sub.4) and evaporated to give an oil. This material in
dichloromethane (50 ml) was treated for 15 min. at 20.degree. C. with
potassium t-butoxide (3 g, 26.79 mmol). After filtration, the material
isolated from the filtrate was chromatographed on silica gel eluting with
ethylacetate-methanol (3.2:1). The title compound was isolated as the
oxalate salt. M.p. 189.0.degree. C.
EXAMPLE 5
3-(3-Isopropyl-1,2,4-oxadiazol-5-yl)-quinuclidine oxalate
Sodium (224 mg, 9.74 mmol) was dissolved in absolute ethanol (45 ml).
Molecular sieves (Type 4A, 5 g) and isopropancarboxamide oxime (993 mg,
9.74 mmol) were added and the resulting mixture vigorously stirred for 15
min. before addition of 3-methoxycarbonyl-quinuclidine HCl prepared as
described by Grob et al. in Helv. Chim. Acta. (1954), 37, 1689. The
reaction mixture was heated at 80.degree. C. for 18 h. The solution was
then filtered from the molecular sieves and the solvent was removed in
vacuo. Ether (50 ml) was added to the residue followed by water (25 ml)
and the organic phase was separated. The aqueous phase was extracated with
ether (3.times.50 ml), and the combined ether phases were dried (Na.sub.2
SO.sub.4) and evaporated to afford the title oxadiazole as an oil. The
product was further purified as the oxalate salt. M.p.
118.degree.-119.degree..
In exactly the same manner the following compounds were prepared:
3-(3-butyl-1,2,4-oxadiazol-5-yl)-quinuclidine oxalate, M.p.
122.degree.-124.degree. C.
3-(3-methoxymethyl-1,2,4-oxadiazol-5-yl)-quinuclidine oxalate, M.p.
107.degree.-108.degree. C.
3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-quinuclidine oxalate, M.p.
156.degree.-157.degree. C.
EXAMPLE 6
1-Benzoyl-4-chloro-3-formyl-1,2,5,6-tetrahydropyridine oxime
To a solution of 14.6 g (200 mmol) dimethylformamide in 50 ml
methylenechloride at 0.degree. C. was added 24.52 g (160 mmol) phosphorus
oxychloride at such a rate that the temperature did not exceed 10.degree.
C. After addition the reaction mixture was stirred for 1 h at room
temperature. The mixture was again cooled to 0.degree. C. and 20.32 g (100
mmol) 1-benzoyl-4-piperidone in 30 ml methylenechloride was added
dropwise. After addition (30 min.), the reaction mixture was stirred at
room temperature for 2 h whereupon, 150 g crushed ice was added and the
mixture stirred until the ice had dissolved. Solid sodium acetate (70 g)
was added, and the mixture stirred for 15 min. The methylenechloride
fraction was isolated and the aqueous portion was extracted with
2.times.50 ml methylenechloride. The combined methylenechloride extracts
were poured in 100 ml of a saturated sodium bicarbonate solution, and the
mixture stirred vigorously for 15 min. The methylenechloride fraction was
then isolated, washed with water, dried over magnesium sulfate and
concentrated to a volume of 50 ml. To this solution was added 100 ml
ethanol, hydroxylamine hydrochloride (6.65 g, 100 mmol) and 15 ml
triethylamine. The reaction mixture was stirred overnight, 200 ml water
was added and the methylenechloride fraction isolated. The aqueous portion
was extracted with 2.times.50 ml methylenechloride. The combined
methylenechloride extracts were dried over magnesiumsulfate, and
concentrated in vacuo. To the remaining oil was added 50 ml ethanol and
the title compound separated out. Yield: 10.5 g. M.p.
175.degree.-176.degree. C.
In exactly the same manner the following compounds were prepared:
1-Methyl-4-chloro-3-formyl-1,2,5,6-tetrahydropyridine oxime from
1-methyl-4-piperidone and hydroxylamine. M.p. 172.degree.-73.degree. C.
1-Benzyl-4-chloro-3-formyl-1,2,5,6-tetradydropyridine oxime from
1-benzyl-4-piperidone and hydroxylamine M.p. 148.degree.-151.degree. C.
1-Methyl-4-chloro-3-methoxyiminomethyl-1,2,5,6-tetrahydropyridine from
1-methyl-4-piperidone and O-methylhydroxylamine. M.p.
185.degree.-187.degree. C. as oxalate.
8-Ethoxycarbonyl-3-chloro-2-formyl-8-azabicyclo[3.2.1]oct-2-ene oxime from
N-(ethoxycarbonyl)nortropan-3-one (G. L. Grunewald et.al. J. Med. Chem.
1988, 31, 433-44). Oil.
EXAMPLE 7
1-Benzoyl-4-chloro-3-(5-methoxymethyl-3-isoxazolyl)-1,2,5,6-tetrahydropyrid
ine
To a solution of 1-benzoyl-4-chloro-3-formyl-1,2,5,6-tetrahydropyridine
oxime (5.3 g, 20 mmol) in 100 ml dry dimethylformamide was added
N-bromosuccinimide (4.5 g, 25 mmol) dissolved in 20 ml dry
dimethylformamide. The reaction mixture was stirred at room temperature
for 1 h. Now methylpropargylether (1.5 ml, 25 mmol) and 2 ml triethylamine
was added and the reaction mixture stirred at room temperature overnight.
200 ml water was added and the aqueous phase extracted with 3.times.50 ml
ether. The combined ether extracts were washed with 2.times.50 ml water,
dried over magnesiumsulfate and concentrated in vacuo. The compound was
finally purified by column chromatography with
methylenechloride/ethylacetate 4:1 as eluent. Yield: 3.5 g. M.p.
60.5.degree.-62.degree. C.
In exactly the same manner the following compounds were prepared
1-Benzoyl-4-chloro-3-(5-butyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine
1-Benzoyl-4-chloro-3-(5-hydroxymethyl-3-isoxazolyl)-1,2,5,6-tetrahydropyrid
ine
1-Benzoyl-4-chloro-3-(5-dimethylaminomethyl-3-isoxazolyl)-1,2,5,6-tetrahydr
opyridine
1-Benzoyl-4-chloro-3-(5-ethoxy-4,5-dihydro-3-isoxazolyl)-1,2,5,6-tetrahydro
pyridine
8-Ethoxycarbonyl-3-chloro-2-(5-butyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2
-ene
8-Ethoxycarbonyl-3-chloro-2-(5-methoxymethyl-3-isoxazolyl)-8-azabicyclo[3.2
.1]oct-2-ene
8-Ethoxycarbonyl-3-chloro-2-(5-phenyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oxt-
2-ene
1-Benzoyl-4-chloro-3-(5-methyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine
To a solution of 1-benzoyl-4-chloro-3-formyl-1,2,5,6-tetrahydropyridine
oxime (5,3 g, 20 mmol) in 100 ml dry dimethylformamide was added
N-bromosuccinimide (4.5 g, 25 mmol) dissolved in 20 ml dry
dimethylformamide. The reaction mixture was stirred at room temperature
for 1 h. Now 2-bromopropene (2.2 ml, 25 mmol) and 4 ml triethylamine were
added and the reaction mixture stirred at room temperature for 48 h. The
compound was purified as described for
1-Benzoyl-4-chloro-3-(5-methoxymethyl-3-isoxazolyl)-1,2,5,6-tetrahydropyri
dine. Yield: 3.1 g. M.p. 86.degree.-87.degree. C.
In exactly the same manner the following compound was prepared
8-Ethoxycarbonyl-3-chloro-2-(5-methyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-
2-ene
EXAMPLE 8
4-Chloro-3-(5-methoxymethyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine
oxalate
A suspension of 1.65 g (5 mmol) of
1-benzoyl-4-chloro-3-(5-methoxymethyl-3-isoxazolyl)-1,2,5,6-tetrahydropyri
dine in 30 ml 6M hydrochloric acid solution was heated at reflux for 5 h.
After cooling to room temperature 30 ml water was added and the aqueous
phase extracted with 2.times.30 ml ether. The aqueous phase was made
strongly alkaline with solid potassiumcarbonate and extracted with
2.times.30 ml ether. The combined ether extracts were dried over
magnesiumsulfate and concentrated in vacuo. The remaining oil was
dissolved in 10 ml acetone, and the title compound was precipitated with a
1M oxalic acid acetone solution. The compound was filtered and dried.
Yield: 0.65 g. M.p. 155.degree.-156.degree. C.
In exactly the same manner the following compounds were prepared
4-Chloro-3-(5-methyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine oxalate
starting from
1-benzoyl-4-chloro-3-(5-methyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine.
M.p. 180.degree.-181.degree. C.
4-Chloro-3-(5-butyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine oxalate
starting from
1-benzoyl-4-chloro-3-(5-butyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine.
M.p. 164.degree.-165.degree. C.
4-Chloro-3-(5-hydroxymethyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine
oxalate starting from
1-benzoyl-4-chloro-3-(5-hydroxymethyl-3-isoxazolyl)-1,2,5,6-tetrahydropyri
dine. M.p. 167.degree.-169.degree. C.
4-Chloro-3-(5-dimethylaminomethyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine
oxalate starting from
1-benzoyl-4-chloro-3-(5-dimethylaminomethyl-3-isoxazolyl)-1,2,5,6-tetrahyd
ropyridine. M.p. 226.degree.-29.degree. C.
4-Chloro-3-(3-isoxazolyl)-1,2,5,6-tetrahydropyridine oxalate starting from
1-benzoyl-4-chloro-3-(5-ethoxy-4,5-dihydro-3-isoxazolyl)-1,2,5,6-tetrahydr
opyridine. M.p. 195.degree.-196.degree. C.
EXAMPLE 9
3-(5-Methoxymethyl-3-isoxazolyl)-1 2 5.6-tetrahydropyridine oxalate
1-Benzoyl-4-chloro-3-(5-methoxymethyl-3-isoxazolyl)-1,2,5,6-tetrahydropyrid
ine (0.8 g, 2.5 mmol) was dissolved in 50 ml ethanol. To this solution was
added a suspension of palladium-on-charcoal (5%, 0.5 g) in 10 ml ethanol
and 2 ml triethylamine. The mixture was reduced with hydrogen at
atmospheric pressure until exactly 1.2 equivalent of hydrogen was
consumed. The catalyst was filtered off and the solution concentrated in
vacuo. The remaining oil was suspended in 20 ml 6M hydrochloric acid
solution and heated at reflux for 5 h. After cooling 20 ml water was added
and the aqueous solution was extracted with 2.times.20 ml ether. The
aqueous solution was made strongly alkaline with solid potassium carbonate
and extracted with 3.times.20 ml methylenechloride. The combined
methylenechloride extracts were dried over magnesiumsulfate and
concentrated in vacuo. The remaining oil was dissolved in 10 ml acetone,
and the title compound was precipitated with a 1M oxalic acid acetone
solution. The compound was filtered and dried. Yield: 0.2 g. M.p.
152.degree.-153.degree. C.
In exactly the same manner the following compounds were prepared:
3-(5-methyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine oxalate starting from
1-benzoyl-4-chloro-3-(5-methyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine.
M.p. 176.degree.-177.degree. C.
3-(5-Butyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine oxalate starting from
1-benzoyl-4-chloro-3-(5-butyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine.
M.p. 188.degree.-91.degree. C.
EXAMPLE 10
3-(5-Propyl-1,2,4-oxadiazol-3-yl)-2,3-didehydroquinuclidine oxalate
To a solution of sodium (575 mg, 25 mmol) in methanol (20 ml) was added a
solution of hydroxylamine hydrochloride (1.55 g, 22 mmol) in methanol (20
ml). The mixture was stirred for 30 min, and filtrated. To the filtrate a
solution of 3-cyano-2,3-didehydroquinuclidine (Helv. Chem. Acta 40, 2170
(1957)) (1.2 g, 9 mmol) in methanol (5 ml) was added and the reaction
mixture was stirred at room temperature for 48 h. After evaporation the
residue was suspended in absolute ethanol (25 ml), filtered and evaporated
to give the 2,3-didehydroquinuclidineamide oxime. The amide oxime (700 mg)
was dissolved in butyric anhydride and stirred at 100.degree. C. for 16 h.
After evaporation the residue was dissolved in a saturated potassium
carbonate solution (10 ml) and extracted with ether (3.times.75 ml). The
combined organic phases were dried and evaporated. The residue was
purified (column chromatography with 1,2-dichloroethane-methanol (9:1) as
eluent). Crystallization as the oxalate salt from acetone gave the title
compound in a 300 mg yield. M.p. 155.degree.-157.degree. C.
3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-2,3-didehydroquinuclidine oxalate
This compound was synthesized as described above using
cyclopropanecarboxylic acid chloride followed by cyclization in refluxing
toluene instead of butyric anhydride. M.p. 170-.degree.172.degree. C.
8-Methyl-2-(5-propyl-1,2,4-oxadiazol-3-yl)-8-azabicyclo[3.2.1]oct-2-ene
oxalate
This compound was synthesized as described above starting from
2-cyano-8-methyl-8-azabicyclo[3.2.1]oct-2-ene [J. C. S. Perkin I, 1981,
1346.degree.-1351]. M.p. 99.degree.-101.degree. C.
EXAMPLE 11
3-(5-Oxazolyl)-1,2,5,6-tetrahydro-1-methylpyridine oxalate
To a solution of 1-methyl-3-formyl-1,2,5,6-tetrahydropyridine hydrochloride
(Mannich Berichte 75, 1480-83, 1942) 1.60 g, 10 mmol) in 20 ml methanol
powdered potassium carbonate (3 g) was added. Then tosylmethylisocyanide
(1.95 g, 10 mmol) was added and the reaction mixture stirred at room
temperature for 2 h. Upon evaporation in vacuo, water (30 ml) was added to
the residue, and the solution was extracted with methylenechloride
3.times.20 ml. The combined methylenechloride extracts were dried over
magnesiumsulfate and evaporated in vacuo. The crude compound was purified
by column chromatography with acetone as eluent. The title compound was
precipitated with a 1M oxalic acid acetone solution, filtered and dried.
M.p. 169.degree.-170.degree. C.
1-Methyl-3-(4-propyl-5-oxazolyl)-1,2,5,6-tetrahydropyridine oxalate
A mixture of 1.07 g (10 mmol) pyridin-3-carbaldehyde 2.61 g (11 mmol)
1-tosyl-1-isocyanobutane and powdered potassium carbonate in methanol (50
ml) was stirred for 12 h at room temperature. The reaction mixture was
concentrated in vacuo and water (100 ml) was added. The water suspension
was extracted with 3.times.30 ml ethylacetate. The organic phase was dried
over magnesiumsulfate and concentrated in vacuo. The residue was dissolved
in 50 ml acetone and 3.12 g (22 mmol) methyliodide was added. The reaction
mixture was stirred overnight at room temperature, concentrated in vacuo
and titurated with ethylacetate. The precipitated crystals were dissolved
in ethanol (50 ml) and treated with 1.06 g (28 mmol) sodiumborohydride.
The mixture was concentrated in vacuo and water (100 ml) was added. The
water suspension was extracted with 3.times.30 ml methylenchloride. The
organic phase was dried over magnesium sulfate and concentrated in vacuo.
The compound was purified by column chromatographay with
ethylacetate/methanol (9:1) as eluent. Crystallization as the oxalate salt
from acetone gave the title compound in a 940 mg yield. M.p.
100.degree.-101.degree. C.
EXAMPLE 12
3-(Cyclopropylmethoxyiminomethyl)-1 2 5.6-tetrahydro-1-methylpyridine
oxalate
To a solution of 1-methyl-3-formyl-1,2,5,6-tetrahydropyridine hydrochloride
(Mannich Berichte 75, 1480-83, 1942) (1.60 g, 10 mmol) in 20 ml ethanol
cyclopropylmethoxyamine hydrochloride (1.24 g, 10 mmol) and triethylamine
(3 ml) were added. The reaction mixture was stirred at room temperature
for 1 h, then evaporated in vacuo. 30 ml sodium hydroxide solution (0.5M)
was added to the residue, and the solution was extracted with
methylenechloride (3.times.20 ml). The combined methylenechloride extracts
were dried and evaporated in vacuo. The residue was dissolved in acetone
and the title compound was precipitated with a 1M oxalic acid acetone
solution. The compound was filtered and dried. M.p.
143.degree.-144.degree. C.
EXAMPLE 13
3-Chloro-2-formyl-8-methyl-8-azabicyclo[3.2.1]oct-2-ene oxalate
To a dimethylformamide (4.5 ml, 60 mmol) at 0.degree. C. was added
phosphorous oxychloride (3 ml, 30 mmol). Tropinone (2 g, 13 mmol) was
added, and the reaction mixture heated to 70.degree. C. for 1/2 h After
cooling, crushed ice was added and then solid potassium carbonate until
alkaline reaction. The water solution was extracted with ether (3.times.30
ml). The ether extracts were dried and evaporated. The crude compound was
purified by column chromatography with acetone as eluent. The title
compound was precipitated with a 1M oxalic acid acetone solution, filtered
and dried. M.p. 136.degree.-137.degree. C. decomposes.
EXAMPLE 14
3-Chloro-2-(cyclopropylmethoxyiminomethyl)-8-methyl-8-azabicyclo[3.2.1]oct-
2-ene oxalate
To a solution of 3-chloro-2-formyl-8-methyl-8-azabicyclo[3.2.1]oct-2-ene
oxalate (0.55 g, 2 mmol) in 20 ml ethanol cyclopropylmethoxyamine
hydrochloride (0.25 g, 2 mmol) and triethylamine (1 ml) was added. The
reaction mixture was stirred at room temperature for 1 h, then evaporated
in vacuo. 20 ml sodiumhydroxide solution (0.5M) was added to t he residue,
and the solution was extracted with methylenechloride (3.times.15 ml). The
combined methylenechloride extracts were dried and evaporated in vacuo.
The residue was dissolved in acetone (10 ml) and the title compound was
precipitated with a 1M oxalic acid acetone solution. The compound was
filtered and dried M.p 170.degree.-171.degree. C.
In exactly the same manner the following compound was prepared:
3-Chloro-2-(methoxyiminomethyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene
oxalate from 3-chloro-2-formyl-8-methyl-8-azabicyclo[3.2.1]oct-2-ene
oxalate and methoxyamine hydrochloride, M.p. 180.degree.-185.degree. C.
EXAMPLE 15
3-Chloro-8-methyl-2-(5-oxazolyl)-8-azabicyclo[3.2.1]oct-2-ene oxalate
To a solution of 3-chloro-2-formyl-8-methyl-8-azabicyclo[3.2.1]oct-2-ene
oxalate (0.55 g, 2 mmol) in 20 ml methanol powdered potassium carbonate
(1.5 g) and tosylmethylisocyanide (0.4 g, 2 mmol) was added. The reaction
mixture was stirred at room temperature for 2 h. Upon evaporation in vacuo
water (30 ml) was added to the residue and the water solution extracted
with methylenechloride (3.times.20 ml). The combined methylenechloride
extracts were dried and evaporated in vacuo. The residue was dissolved in
ethanol, and the title compound precipitated with a 1M oxalic acid ether
solution. The compound was filtered and dried. M.p. 69.degree.-71.degree.
C. decomposes.
EXAMPLE 16
2-Methoxyiminomethyl-8-methyl-8-azabicyclo[3.2.1]oct-2-ene oxalate
To a solution of 2-formyl-8-methyl-8-azabicyclo[3.2.1]oct-2-ene (T. Bacesov
and M. Shives, J. Am. Chem. Soc., 107, 7524-33, 1985) (0.3 g, 2 mmol) in
20 ml ethanol methoxyamine hydrochloride (0.17 g, 2 mmol) and
triethylamine 0.5 ml was added. The reaction mixture was stirred at room
temperature for 1 h, then evaporated in vacuo. Sodiumhydroxide solution
(20 ml, 0.5 mmol) was added to the residue and the solution was extracted
with methylenechloride (3.times.15 ml). The combined methylenechloride
extracts were dried and evaporated in vacuo. The residue was dissolved in
acetone (5 ml) and the title compound was precipitated with a 1M oxalic
acid acetone solution. The compound was filtered and dried. M.p.
129.degree.-130.degree. C.
In exactly the same manner the following compound was prepared:
2-Ethoxyiminomethyl-8-methyl-8-azabicyclo[3.2.1]oct-2-ene oxalate from
2-formyl-8-methyl-8-azabicyclo[3.2.1]oct-2-ene and ethoxyamine
hydrochloride. M.p. 127.degree.-128.degree. C.
EXAMPLE 17
3-(3-Cyclobutyl-1,2,4-oxadiazol-5-yl)-1-methyl-1,2,5,6-tetrahydropyridine
oxalate
To a solution of sodium ethoxide (prepared from sodium (34 mg, 1.48 mmol),
destilled ethanol (20 ml) and molecular sieves (4 g) was added
cyclobutancarboxamide oxime (169 mg, 1.48 mmol). The mixture was stirred
at room temperature for 10 min. and arecoline, hydrobromide (175 mg, 0.74
mmol) was added. The reaction mixture was stirred at 80.degree. C. for 18
h, filtered and evaporated. Water (10 ml) was added to the residue, and
the solution was extracted with ether (3.times.30 ml). The combined ether
phases were dried and evaporated to give the crude product as an oil.
Crystallization as the oxalate salt from absolute ethanol gave the title
compound in a yield of 60 mg. M.p. 148.degree.-149.degree. C.
In exactly the same manner the following compounds were prepared:
3-(3-cyclopentyl-1,2,4-oxadiazol-5-yl)-1-methyl-1,2,5,6-tetrahydropyridine
oxalate. M.p. 132.degree.-133.degree. C.
3-(3-(2-methoxyethyl)-1,2,4-oxadiazol-5-yl)-1-methyl-1,2,5,6-tetrahydropyri
dine oxalate. M.p. 140.degree.-141.degree. C.
3-(3-(2-ethoxyethyl)-1,2,4-oxadiazol-5-yl)-1-methyl-1,2,5,6-tetrahydropyrid
ine oxalate. M.p. 143.degree.-144.degree. C.
3-(3-(2-methoxybenzyl)-1,2,4-oxadiazol-5-yl)-1-methyl-1,2,5,6-tetrahydropyr
idine oxalate. M.p. 76.degree.-77.degree. C.
Using norarecoline instead of arecoline the following compounds were made
in exactly the same manner as described above:
3-(3-cyclobutyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine oxalate.
M.p. 202.degree.-205.degree. C.
3-(3-cyclopentyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine oxalate.
M.p. 152.degree.-158.degree. C.
EXAMPLE 18
3-(5-Isoxazolyl)-1-methyl-1,2,5,6-tetrahydropyridine oxalate
A mixture of 12.1 g (0.1 mol) 3-acetyl pyridine and 15 g (0.11 mol)
dimethyl formamide dimethylacetale was heated at 90.degree. C. for 2 h.
Upon concentration in vacuo the product was titrated with ethylether and
filtrated. The compound was dissolved in 50 ml methanol and 11.5 g (0.1
mol) hydroxylamine-O-sulfonic acid dissolved in 50 ml MeOH was added. The
reaction mixture was stirred at room temperature for 2 h, concentrated in
vacuo and poured on water (150 ml). The solution was made alkaline with
solid potassium carbonate and extracted with 4.times.40 ml
methylenchloride. The organic phase was dried over magnesium sulfate and
concentrated in vacuo. The crude product was purified by column
chromatography giving 1.5 g 3-(5-isoxazolyl)-pyridine, which was dissolved
in 20 ml acetone. 3 ml methyliodide was added to the solution, and the
reaction mixture was stirred at room temperature for 24 h. The
precipitated compound was filtered and dissolved in 30 ml methanol. To
this solution sodiumborohydride (600 mg) was added in small portions. The
reaction mixture was concentrated in vacuo and water (100 ml) was added.
The water solution was extracted with 3.times.30 ml methylenchloride. The
organic phase was dried over magnesiumsulfate and concentrated in vacuo.
Crystallization as the oxalate salt from acetone gave the title compound
in a 1.1 g yield. M.p. 164.degree.-165.degree. C.
3-(3-Methyl-5-isoxazolyl)-1,2,5,6-tetrahydropyridine oxalate
This compound was prepared as described above starting from
3-acetylpyridine and dimethylacetamide dimethylacetale. M.p.
167.degree.-169.degree. C.
3-(3-Ethyl-5-isoxazolyl)-1-methyl-1,2,5,6-tetrahydropyridine oxalate
0.45 g (5 mmole) nitropropane and 5 ml 1N (5 mmole) sodiummethoxide was
dissolved in dry dimethylacetamide (25 ml). To this solution 0.39 g (5
mmole) acetylchloride and 0.51 g (5 mmole) 2-ethynylpyridine was added.
The reaction mixture was stirred overnight at room temperature. Water (150
ml) was added, and the solution extracted with 3.times.30 ml ethylacetate.
The organic phase was dried over magnesiumsulphate and concentrated in
vacuo giving 3-(3-ethyl-5-isoxazolyl)pyridine in a 500 mg yield. This
compound was quartarnized with methyliodide and reduced with
sodiumborohydride as described above giving the title compound in a 170 mg
yield. M.p. 169.degree.-170.degree. C.
EXAMPLE 19
3-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)-1,4-dimethyl-1,2,5,6-tetrahydropyrid
ine oxalate
Sodium (54.4 mg, 2.37 mmol) was dissolved in absolute ethanol (10 ml).
Molecular sieves (Type 4 .ANG., 1 g) and cyclopropanylcarboxamide oxime
(236 mg, 2.37 mmol) were added and the resulting mixture vigorously
stirred for 15 min. before addition of
1,4-dimethyl-3-methoxycarbonyl-1,2,5,6-tetrahydropyridine oxalate (200 mg,
1.18 mmol). The reaction mixture was heated at 80.degree. C. for 18 h. The
solution was then filtered from the molecular sieves and the solvent was
removed in vacuo. Ether (40 ml) was added to the residue followed by water
(15 ml) and the organic phase was separated. The aqueous phase was
extracted with ether (3.times.40 ml), and the combined ether phases were
dried (Na.sub.2 SO.sub.4) and evaporated to afford the title oxadiazole as
an oil. The product was further purified as the oxalate salt. M.p.
152.degree.-153.degree. C.
In exactly the same manner the following compound was prepared:
3-(3-Butyl-1,2,4-oxadiazol-5-yl)-1,4-dimethyl-1,2,5,6-tetrahydropyridine
oxalate. M.p. 147.degree.-148.degree. C.
EXAMPLE 20
3-Chloro-2-(5-butyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene oxalate
To a solution of 1.0 g (3 mmol) of
8-ethoxycarbonyl-3-chloro-2-(5-butyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-
2-ene in dry toluene (20 ml), 2 g (15 mmol) aluminiumtrichloride was added.
The reaction mixture was heated at 70.degree. C. for 15 min., then cooled
and poured on ice water (100 ml). The phases were separated and the water
phase extracted with 2.times.20 ml ethylether. The water phase was made
alkaline With a sodiumhydroxide solution (2 N), and extracted with
3.times.30 ml methylenchloride. The organic phase was dried over
magnesiumsulphate and concentrated in vacuo. Crystallization as the
oxalate salt from acetone gave the title compound in a 450 mg yield. M.p.
112.degree.-114.degree. C.
In exactly the same manner the following compounds were prepared:
3-Chloro-2-(5-methoxymethyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene
oxalate. M.p. 153.degree.-154.degree. C.
3-Chloro-2-(5-phenyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene oxalate.
M.p. 135.degree.-136.degree. C.
3-Chloro-2-(5-methyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene oxalate.
M.p. 136.degree.-137.degree. C.
2-(5-phenyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene oxalate. M.p.
163.degree.-164.degree. C.
EXAMPLE 21
8-Ethoxycarbonyl-2-(5-phenyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene
1.3 g (3.6 mmol)
8-ethoxycarbonyl-3-chloro-2-(5-phenyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct
-2-ene was dissolved in 30 ml ethanol. 300 mg Pd/C 5%, triethylamine (7 ml)
and formic acid (3 ml) was added and the reaction mixture heated at reflux
for 4 h. The mixture was concentrated in vacuo, water (50 ml) was added
and the solution extracted with ethylether 3.times.20 ml. The organic
phase was dried over magnesiumsulphate and concentrated in vacuo. The
crude product was purified by column chromatography with
methylenchloride/ethylacetate (9:1) as eluent. Yield 600 mg oil.
EXAMPLE 22
4-Chloro-3-(5-methoxymethyl-3-isoxazolyl)-1-methyl-1,2,5,6-tetrahydropyridi
ne oxalate
To a mixture of formic acid (5 ml) and formaldehyde 37% (10 ml) 1.6 g (5
mmole)
4-chloro-3-(5-methoxymethyl-3-isoxazolyl)-1,2,5,6-tetrahydropyridine oxala
te was added. The reaction mixture was heated at reflux for 1 h. After
cooling the reaction mixture was poured on water (50 ml) and made alkaline
with solid potassiumcarbonate. The water phase was extracted with
3.times.30 ml methylenchloride. The organic phases were dried over
magnesiumsulphate and concentrated in vacuo. Crystallization as the
oxalate salt from acetone gave the title compound in a 1.25 g yield. M.p.
171.degree.-172.degree. C.
In exactly the same manner the following compounds were prepared:
3-Chloro-8-methyl-2-(5-methyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene
oxalate with
3-chloro-2-(5-methyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene oxalate as
starting compound. M.p. 149.degree.-150.degree. C.
3-Chloro-8-methyl-2-(5-phenyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene
oxalate with
3-chloro-2-(5-phenyl-3-isoxazolyl)-8-azabicyclo[3.2.1]oct-2-ene oxalate as
starting compound. M.p. 260.degree.-261.degree. C.
Top